APA (7th ed.) Citation

IF, K., K, A., H, K., DR, M., AM, G., K, S., . . . EJ, J. (2024). Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. American journal of hematology, 99(5), 836. https://doi.org/10.1002/ajh.27254

Chicago Style (17th ed.) Citation

IF, Khouri, et al. "Safety and Long-term Survival Results of the Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation: A Single-center Phase 1,2 Trial." American Journal of Hematology 99, no. 5 (2024): 836. https://doi.org/10.1002/ajh.27254.

MLA (9th ed.) Citation

IF, Khouri, et al. "Safety and Long-term Survival Results of the Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation: A Single-center Phase 1,2 Trial." American Journal of Hematology, vol. 99, no. 5, 2024, p. 836, https://doi.org/10.1002/ajh.27254.